These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 11315008)

  • 1. Efficiency of estimating vaccine efficacy for susceptibility and infectiousness: randomization by individual versus household.
    Datta S; Halloran ME; Longini IM
    Biometrics; 1999 Sep; 55(3):792-8. PubMed ID: 11315008
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomization and baseline transmission in vaccine field trials.
    Struchiner CJ; Halloran ME
    Epidemiol Infect; 2007 Feb; 135(2):181-94. PubMed ID: 17291359
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estimating vaccine efficacy from household data observed over time.
    Davis XM; Haber M
    Stat Med; 2004 Oct; 23(19):2961-74. PubMed ID: 15351955
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Causal inference for vaccine effects on infectiousness.
    Halloran ME; Hudgens MG
    Int J Biostat; 2012 Jan; 8(2):. PubMed ID: 22499732
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estimating vaccine effects on transmission of infection from household outbreak data.
    Becker NG; Britton T; O'Neill PD
    Biometrics; 2003 Sep; 59(3):467-75. PubMed ID: 14601747
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Implications of genetic traits on vaccine efficacy.
    Murthy BN
    Stat Med; 2003 Jun; 22(12):1989-98. PubMed ID: 12802817
    [TBL] [Abstract][Full Text] [Related]  

  • 7. "Spatial heterogeneity of environmental risk in randomized prevention trials: consequences and modeling".
    Guindo A; Sagara I; Ouedraogo B; Sallah K; Assadou MH; Healy S; Duffy P; Doumbo OK; Dicko A; Giorgi R; Gaudart J
    BMC Med Res Methodol; 2019 Jul; 19(1):149. PubMed ID: 31307393
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Augmented designs to assess immune response in vaccine trials.
    Follmann D
    Biometrics; 2006 Dec; 62(4):1161-9. PubMed ID: 17156291
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A stochastic model of vaccine trials for endemic infections using group randomization.
    Riggs TW; Koopman JS
    Epidemiol Infect; 2004 Oct; 132(5):927-38. PubMed ID: 15473157
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estimating vaccine efficacy from outbreak size household data in the presence of heterogeneous transmission probabilities.
    Davis XM; Waller LA; Haber M
    J Biopharm Stat; 2006; 16(4):499-516. PubMed ID: 16892910
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estimating influenza vaccine efficacy from challenge and community-based study data.
    Basta NE; Halloran ME; Matrajt L; Longini IM
    Am J Epidemiol; 2008 Dec; 168(12):1343-52. PubMed ID: 18974084
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimal vaccine trial design when estimating vaccine efficacy for susceptibility and infectiousness from multiple populations.
    Longini IM; Sagatelian K; Rida WN; Halloran ME
    Stat Med; 1998 May; 17(10):1121-36. PubMed ID: 9618773
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sensitivity analyses comparing outcomes only existing in a subset selected post-randomization, conditional on covariates, with application to HIV vaccine trials.
    Shepherd BE; Gilbert PB; Jemiai Y; Rotnitzky A
    Biometrics; 2006 Jun; 62(2):332-42. PubMed ID: 16918897
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Augmented HIV vaccine trial design for estimating reduction in infectiousness and protective efficacy.
    Datta S; Halloran ME; Longini IM
    Stat Med; 1998 Jan; 17(2):185-200. PubMed ID: 9483728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sensitivity analysis for the assessment of causal vaccine effects on viral load in HIV vaccine trials.
    Gilbert PB; Bosch RJ; Hudgens MG
    Biometrics; 2003 Sep; 59(3):531-41. PubMed ID: 14601754
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of sample size for estimating efficacy of a vaccine against an infectious disease.
    Carpenter TE
    Am J Vet Res; 2001 Oct; 62(10):1582-4. PubMed ID: 11592323
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Semiparametric methods for multiple exposure mismeasurement and a bivariate outcome in HIV vaccine trials.
    Golm GT; Halloran ME; Longini IM
    Biometrics; 1999 Mar; 55(1):94-101. PubMed ID: 11318183
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pseudo cluster randomization: a treatment allocation method to minimize contamination and selection bias.
    Borm GF; Melis RJ; Teerenstra S; Peer PG
    Stat Med; 2005 Dec; 24(23):3535-47. PubMed ID: 16007575
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimal vaccination strategies for a community of households.
    Becker NG; Starczak DN
    Math Biosci; 1997 Jan; 139(2):117-32. PubMed ID: 9009574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomization for the susceptibility effect of an infectious disease intervention.
    Eck DJ; Morozova O; Crawford FW
    J Math Biol; 2022 Sep; 85(4):37. PubMed ID: 36127558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.